secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001933414-23-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys FY2022 net loss $29.8M; cash $110.1M plus $202M IPO; lorundrostat pivotal trials H1 2023
--------------------------------------------------------------------------------

- Net loss for FY2022 was $29.8M vs $19.4M in FY2021, driven by higher R&D and G&A costs.
- Cash and marketable securities were $110.1M at Dec 31, 2022; Feb 2023 IPO raised net ~$202M.
- Positive Phase 2 Target-HTN data presented; FDA end-of-Phase 2 meeting completed.
- Pivotal ADVANCE-HTN Phase 2 trial planned H1 2023; Phase 3 trial planned H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000009/0001933414-23-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000009/mlys20230315-8kfy2022.htm
  HTML page:      https://secwatch.observer/filing/0001933414-23-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer